$370M Cash Deal As B-MS Sells Linvatec

6 January 1998

Linvatec Corp, a wholly-owned subsidiary of Bristol-Myers Squibb, hasbeen acquired by the CONMED Corp. Terms of the acquisition of Linvatec, a surgical device company, include a cash purchase price of $370 million, subject to certain adjustments. In addition, B-MS has received a 10-year warrant to purchase one million shares of CONMED stock at a price equal to $34.23 per share. Linvatec had revenues of approximately $215 million in 1996 and employs 850 people.

- Meantime, B-MS has acquired Redmond Products, a privately-owned US hair care company which has sales of some $130 million per year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight